Benlloch Salvador, Berenguer Marina, Prieto Martín, Moreno Rosalba, San Juan Fernando, Rayón Miguel, Mir Jose, Segura Angel, Berenguer Joaquín
Department of Hepato-Gastroenterology, Hospital Universitario La Fe, Valencia, Spain.
Am J Transplant. 2004 Apr;4(4):596-604. doi: 10.1111/j.1600-6143.2004.00380.x.
The goal of the study was to determine the incidence and variables associated with post-liver transplantation (LT) de novo internal neoplasms development, excluding skin tumors and hepatocellular carcinoma. Medical records were reviewed for recipient/donor demographics, viral serology, cause of liver disease, interval from LT to tumor diagnosis, predisposing factors, immunosuppression and survival. Forty-one neoplasms (31 solid and 10 hematologic) developed in 772 recipients (5.3%) transplanted between 1991 and 2001. Time to tumor diagnosis was longer in patients transplanted before 1995 than in those transplanted afterwards (58 vs. 22 months; p<0.05). Hematologic neoplasms (HN) appeared earlier than solid (2 vs. 21 months; p<0.001), were more prevalent in those transplanted after 1995 than before (32% vs. 12.5%), and had lower survival than solid (2 vs. 21 months, p<0.001). While HCV was the most frequent indication in HN (70%), alcohol was that of solid tumors (71%). Overall, risk factors for de novo neoplasms included alcohol and immunosuppression (p<0.01). In patients undergoing LT in recent years, there is a higher incidence of HN with de novo internal neoplasms developing at earlier time-points than in those transplanted years ago. Risk factors for tumor development include alcohol, HCV and possibly strong immunosuppression.
本研究的目的是确定肝移植(LT)后新发内脏肿瘤(不包括皮肤肿瘤和肝细胞癌)的发病率及相关变量。回顾了受者/供者的人口统计学资料、病毒血清学、肝脏疾病病因、从肝移植到肿瘤诊断的时间间隔、易感因素、免疫抑制情况及生存情况。1991年至2001年间接受移植的772例受者中发生了41例肿瘤(31例实体瘤和10例血液系统肿瘤)(5.3%)。1995年前接受移植的患者肿瘤诊断时间比之后接受移植的患者更长(58个月对22个月;p<0.05)。血液系统肿瘤(HN)比实体瘤出现得更早(2个月对21个月;p<0.001),在1995年后接受移植的患者中比之前更常见(32%对12.5%),且生存率低于实体瘤(2个月对21个月,p<0.001)。虽然丙型肝炎病毒(HCV)是血液系统肿瘤最常见的病因(70%),但酒精是实体瘤的最常见病因(71%)。总体而言,新发肿瘤的危险因素包括酒精和免疫抑制(p<0.01)。近年来接受肝移植的患者中,血液系统肿瘤的发病率更高,新发内脏肿瘤在更早的时间点出现,比多年前接受移植的患者情况更严重。肿瘤发生的危险因素包括酒精、HCV以及可能存在的强效免疫抑制。